Navigation Links
Cell Therapeutics, Inc. Announces Institutional Investors Purchase $30 Million of Preferred Stock and Warrants
Date:6/29/2011

SEATTLE, June 30, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (Nasdaq and MTA:CTIC) (the "Company") today announced that it has entered into an agreement to sell, subject to customary closing conditions, $30 million of shares of its Series 13 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to six institutional investors. Each share of Series 13 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 588 shares of common stock at a conversion price of $1.70 per share of common stock, for a total of approximately 17,647,059 shares of common stock.

In connection with the offering, the investors received warrants to purchase up to 8,820,000 shares of common stock. The warrants have an exercise price of $2.15 per warrant share, for total potential additional proceeds to the Company of approximately $19 million upon exercise of the warrants for cash. The warrants are exercisable beginning six months and one day after the date of issuance and expire five years and one day after the date of issuance.

The Company intends to use the net proceeds from the offering for general corporate purposes, which may include, among other things, paying interest on and/or retiring portions of its outstanding debt, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications and general working capital. The Company may also use a portion of the net proceeds to fund possible investments in, or acquisitions of, complementary businesses, technologies or products. The Company has recently engaged in limited discussions with third parties regarding such investments or acquisitions, but has no current agreements or commitments with respect to any investment or acquisition.

Shares of the Series 13 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock and have no voting rights on general corporate matters.

The closing of the offering is expected to occur on July 5, 2011, at which time the Company will receive the cash proceeds and deliver the securities.

Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq: RODM), acted as the exclusive placement agent for the offering.  Trout Capital LLC provided financial advisory services.

A shelf registration statement relating to the shares of Series 13 Preferred Stock and warrants issued in the offering (and the shares of common stock issuable upon conversion of the Series 13 Preferred Stock and exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC"). A prospectus supplement under Rule 424 of the Securities Act of 1933, as amended, relating to the offering will be filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting the Company at the following address: Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This press release does not constitute an offer to sell or a solicitation of an offer to buy the Series 13 Preferred Stock or warrants (or the shares of common stock issuable upon conversion of the Series 13 Preferred Stock and exercise of the warrants). No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading prices of the Company's securities. The risks and uncertainties include the risk that the purchase and sale of the Series 13 Preferred Stock and related warrants might not be consummated, investors might not exercise their warrants, the Company's intentions regarding the use of proceeds, and other risk factors listed or described from time to time in the Company's filings with the SEC, including, without limitation, its most recent filings on Forms 10-K, 10-Q and 8-K. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.

Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
F: 206.272.4434
E: deramian@ctiseattle.com
www.celltherapeutics.com/media.htm

Investors Contact:
Ed Bell
T: 206.282.7100
Lindsey Jesch Logan
T: 206.272.4347
F: 206.272.4434
E: invest@ctiseattle.com
www.celltherapeutics.com/investors

www.CellTherapeutics.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
2. Serina Therapeutics, Inc. Closes $9.5 Million Financing Round
3. Cancer Research UK Signs Deal With Centella Therapeutics, Inc. to Launch Clinical Development of Radiotherapy-Enhancing Drug
4. Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
5. Cell Therapeutics, Inc. Reports First Quarter Accomplishments and Financial Results
6. Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Maintains Target Price of $6.50
7. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
8. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2010 Financial Results on February 16
9. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
10. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®
11. Veteran Pharmaceutical Executives Form New American Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... CAMBRIDGE , United Kingdom and  BOSTON ... text analytics provider Linguamatics today announced ... Dow Jones . The agreement allows pharmaceutical companies ... utilizing Linguamatics I2E text mining technology. ... used by 18 of the top 20 global ...
(Date:3/28/2017)... 28, 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... Medicines Agency (EMA) has notified the company that ... Authorisation Application (MAA) has passed validation, and that ... The MAA for ARX-04 (known as DSUVIA™ in ...
(Date:3/28/2017)... -- The global flow cytometry market ... 2025, according to a new study by Grand View ... cancer is expected to upsurge the demand for flow ... years. In addition, higher number of physicians is inclined ... therapy, due to adverse effects caused by chemotherapy & ...
Breaking Medicine Technology:
(Date:3/28/2017)... , ... March 28, 2017 , ... Usually, the impending ... daily wardrobe. However, for those self-conscious about a double chin, this means more anxiety ... ideal solution. , “For most people, a double chin is undesirable,” Dr. Goldman ...
(Date:3/28/2017)... ... March 28, 2017 , ... Qualidigm ... its corporate headquarters to a new, more expansive office space in order to ... Qualidigm purchased a distressed office building in Wethersfield, Conn. located at 936 Silas ...
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... ... 28, 2017 , ... AutismOne announced the Board Certified in ... Medicine and available for application on Saturday, May 27, 2017, following Thursday, Friday, ... Springs. , Ed Arranga, president of AutismOne, stated: "Many of the modalities termed ...
(Date:3/28/2017)... , ... March 28, 2017 , ... With expansion and ... Georgia, in early March. , The seed processing plant opened in Marshallville in 2006, ... 2016. The new office allows opportunity for transition of Patten Seed operations to the ...
Breaking Medicine News(10 mins):